BioCentury
ARTICLE | Clinical News

Staccato loxapine: Phase III data

September 8, 2008 7:00 AM UTC

Top-line data from a double-blind, U.S. Phase III trial in 344 patients showed that 10 mg of inhaled AZ-004 met all primary and secondary endpoints, and 5 mg met the primary but not all secondary endp...